Prosecution Insights
Last updated: October 04, 2026

K&L Gates Llp-Boston

Technology area: Biotechnology & Pharmaceuticals

29 pending office actions • 18 clients • 27 examiners • 23 art units • 0 of 29 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days

Analysis

K&L Gates LLP-Boston operates in Biotechnology & Pharmaceuticals. It has 34213 career applications. The firm has a resolved allowance rate of 84.55 percent. It averages 3.82 office actions per allowance. There are 22 pending office actions.

The 84.55 percent allowance rate is derived from 34213 career applications. The average of 3.82 office actions per allowance reflects the typical interaction with the patent office. The 22 pending office actions represent the firm's current workload in the biotechnology sector.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=34213 apps, methodology: how we score firms)

84.6%
Allowance Rate
n=34213
+0.65σ
Allowance Rate (norm)
n=34213
3.8
OAs to Allowance
n=20667
+0.03σ
OAs to Allow (norm)
n=20667
1082 days
Time to Allowance
n=20667
+8.9pp
Interview Lift
n=34213
32.5%
RCE Rate
n=34213
2.7%
Appeal Rate
n=34213

Rejection Performance (% of received rejections ultimately overcome)

76.2%
§101 Overcome
n=2437
77.2%
§102 Overcome
n=9011
77.9%
§103 Overcome
n=15242
77.9%
§112 Overcome
n=10440

Specialization & Scale

A61K, H01M, G06F
Top CPC Subclasses
13%
Top-3 CPC Share
n=34213
90
Practitioners
n=34213
380.1
Apps / Practitioner
n=34213

Portfolio Summary

29
Total Pending OAs
18
Non-Final OAs
8
Final Rejections
3
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

8
Overdue
0
Due this week
3
Due this month
4
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (8)Due ≤ 30 days (3)Due ≤ 60 days (4)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

16
Hard (55%)
11
Medium (38%)
2
Easy (7%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only2 (7%)
§101 + other2 (7%)
§103 only4 (14%)
§102 only1 (3%)
§112 only2 (7%)
Double-patenting + other6 (21%)
Multi-statute (no §101)12 (41%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

19
Life Sciences
66% of docket
2
Information Tech
7% of docket
1
Communications
3% of docket
0
Semiconductors
0% of docket
5
Mechanical / Eng
17% of docket
2
Business / Other
7% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

290 h
Manual time on pending OAs
58 h
Time saved (low, 20%)
102 h
Time saved (mid, 35%)
2.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
XU, MICHAEL 2 75.8% +27.6%
HUDSON, AMY ROSE 2 74.9% +11.5%
KAMM, JUDITH MARIE 1 43.5% +56.6%
PHAM, KATHERINE-PH MINH 1 59.0% +50.4%
STEPHENS, AMELIA CAROLE 1 85.7% +33.3%
NORRIS, CLAIRE A 1 65.8% +28.0%
MAHLUM, JONATHAN DAVIS 1 51.4% +25.6%
PIHONAK, SARAH 1 61.3% +42.6%
SHIAO, YIH-HORNG 1 72.5% +75.9%
INAM, SAHAR 1 100.0% +0.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18721114 TIGIT ANTIBODIES AND USES THEREOF STEPHENS, AMELIA CAROLE —

Hard Cases (16)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17730900 Automated Healthcare Provider Quality Reporting System (PQRS) HEIN, DEVIN C 99d overdue
18643059 MAGNETIC FILTER APPARATUS AND METHOD NORRIS, CLAIRE A 60d overdue
16825087 Systems and Methods of Generating Patient Notes with Inherited Preferences WINSTON III, EDWARD B 60d overdue
17364497 METHOD AND SYSTEM OF GUIDING A USER ON A GRAPHICAL INTERFACE WITH COMPUTER VISION BROUGHTON, KATHLEEN M 15d overdue
17927497 MEMBRANE EMULSIFICATION APPARATUS WITH REFINER AND METHOD OF PREPARING A REFINED EMULSION BASS, DIRK R 12d
18016143 METHOD OF PREPARING LIPID VESICLES SHOMER, ISAAC 20d
18282082 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND LEE, CHIHYI NMN 36d
18037505 ERYTHROPOIETIN VARIANTS AND USES THEREOF KOMATSU, LI N 56d

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18643059 MAGNETIC FILTER APPARATUS AND METHOD NORRIS, CLAIRE A 60d overdue
18998271 CONTINUOUS PROCESS KAMM, JUDITH MARIE —
18984246 ASPIRATORS, COMPONENTS THEREOF, AND ASSEMBLY AND FIT THEREOF PHAM, KATHERINE-PH MINH —
18721114 TIGIT ANTIBODIES AND USES THEREOF STEPHENS, AMELIA CAROLE —
18627032 DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF MAHLUM, JONATHAN DAVIS —
18690561 PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF PIHONAK, SARAH —
18434386 IONIZABLE LIPID COMPOUNDS SHIAO, YIH-HORNG —
18399497 SOFTWARE BASED VALIDATION OF MEMORY FOR FAULT TOLERANT SYSTEMS XU, MICHAEL —

Client Portfolio (18 clients)

Top Art Units

Art UnitApps
16363
17792
21132
16451
16251
16271
16911
16221
16711
16281

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18998271 CONTINUOUS PROCESS Micropore Technologies Limited KAMM, JUDITH MARIE §102§103§112DP Non-Final OA — Pending Jan 24, 2025
18984246 ASPIRATORS, COMPONENTS THEREOF, AND ASSEMBLY AND FIT THEREOF Surgimark, Inc. PHAM, KATHERINE-PH MINH §103§112Other Non-Final OA — Pending Dec 17, 2024
18721114 TIGIT ANTIBODIES AND USES THEREOF Shanghai Nigene Biological Science And Technology Co., Ltd. STEPHENS, AMELIA CAROLE 1645 §112 Non-Final OA — Pending Jun 17, 2024
18643059 MAGNETIC FILTER APPARATUS AND METHOD Medisieve Ltd. NORRIS, CLAIRE A 1779 §102§103 Non-Final OA 60d overdue Pending Apr 23, 2024
18627032 DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF Inxmed (Nanjing) Co., Ltd. MAHLUM, JONATHAN DAVIS 1625 §102§112DP Non-Final OA — Pending Apr 04, 2024
18690561 PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF Coherent Biopharma (Suzhou) Limited PIHONAK, SARAH 1627 §103§112DP Non-Final OA — Pending Mar 08, 2024
18434386 IONIZABLE LIPID COMPOUNDS Metis Techbio Co., Ltd. SHIAO, YIH-HORNG 1691 §102§103§112DP Non-Final OA — Pending Feb 06, 2024
18292582 METHODS OF TREATING CANCER Foghorn Therapeutics Inc. INAM, SAHAR 1622 §102§103 Non-Final OA — Pending Jan 26, 2024
18420532 FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS VISTERRA, INC. GILL, RACHEL B 1671 §102 Non-Final OA 46d Pending Jan 23, 2024
18399497 SOFTWARE BASED VALIDATION OF MEMORY FOR FAULT TOLERANT SYSTEMS Stratus Technologies Ireland Ltd. XU, MICHAEL 2113 §103§112 Non-Final OA — Pending Dec 28, 2023
18282082 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED LEE, CHIHYI NMN 1628 §103§112 Final Rejection 36d Pending Sep 14, 2023
18037884 CONJUGATE AND USE THEREOF Nanjing Chempion Biotechnology Co., Ltd. HOPKINS, SAMANTHA LAKE 1641 §103§112 Non-Final OA — Pending May 19, 2023
18037505 ERYTHROPOIETIN VARIANTS AND USES THEREOF Chulabhorn Foundation KOMATSU, LI N 1658 §102§103§112 Non-Final OA 56d Pending May 17, 2023
18248988 NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR Sanofi VANHORN, ABIGAIL LOUISE 1636 §103§112DP Final Rejection 20d Pending Apr 13, 2023
18248982 NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 Sanofi HUDSON, AMY ROSE 1636 §102§103§112 Final Rejection — Pending Apr 13, 2023
18248974 RNA COMPOSITIONS AND METHODS FOR INHIBITING LIPOPROTEIN(A) Sanofi ARIETI, RUTH SOPHIA 1635 §103DP Final Rejection 3d overdue Pending Apr 13, 2023
18106550 HIGH RELIABILITY FAULT TOLERANT COMPUTER ARCHITECTURE Stratus Technologies Ireland Ltd. XU, MICHAEL 2113 §103 Non-Final OA — Pending Feb 07, 2023
18018078 METHODS OF PREPARING SOLID PARTICULATE MATERIALS Micropore Technologies Limited HUANG, RYAN 1777 §103 Final Rejection 107d overdue Pending Jan 26, 2023
18016143 METHOD OF PREPARING LIPID VESICLES Micropore Technologies Limited SHOMER, ISAAC 1612 §103§112 Non-Final OA 20d Pending Jan 13, 2023
17927497 MEMBRANE EMULSIFICATION APPARATUS WITH REFINER AND METHOD OF PREPARING A REFINED EMULSION Micropore Technologies Limited BASS, DIRK R 1779 §102§103 Non-Final OA 12d Pending Nov 23, 2022
17730900 Automated Healthcare Provider Quality Reporting System (PQRS) Modernizing Medicine, Inc. HEIN, DEVIN C 3686 §101§103 Non-Final OA 99d overdue Pending Apr 27, 2022
17638339 COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 Sanofi HUDSON, AMY ROSE 1636 §102§103§112 Non-Final OA — Pending Feb 25, 2022
17364497 METHOD AND SYSTEM OF GUIDING A USER ON A GRAPHICAL INTERFACE WITH COMPUTER VISION Edcast Inc. BROUGHTON, KATHLEEN M 2661 §102§103 Non-Final OA 15d overdue Pending Jun 30, 2021
16980207 METHOD OF TREATMENT Nuchido Limited OLSON, ANDREA STEFFEL 1693 §103 Final Rejection 73d overdue Pending Sep 11, 2020
16849141 Apparatus and Method for Assessment of Patient Condition Modernizing Medicine, Inc. NAJARIAN, LENA 3687 §103 Non-Final OA 34d Pending Apr 15, 2020
16825087 Systems and Methods of Generating Patient Notes with Inherited Preferences Modernizing Medicine, Inc. WINSTON III, EDWARD B 3683 §101 Non-Final OA 60d overdue Pending Mar 20, 2020
16631861 METHODS AND COMPOSITIONS FOR TREATING ADDICTIONS BAR ILAN UNIVERSITY VIVLEMORE, TRACY ANN 1638 §112 Final Rejection 3d overdue Pending Jan 17, 2020
16412389 SYSTEM AND METHOD FOR SHOWING, TESTING AND CERTIFYING USERS IN-APP ON CLOUD APPLICATION WORKFLOWS Edcast Inc. PRATT, EHRIN LARMONT 3629 §101§103 Non-Final OA — Pending May 14, 2019
15992148 METHODS AND SYSTEMS FOR ANIMATED WALKTHROUGHS IN AN ONLINE EDUCATIONAL PLATFORM Edcast Inc. GRANT, MICHAEL CHRISTOPHER 3715 §101 Final Rejection — Pending May 29, 2018

Managing K&L Gates Llp-Boston's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month